These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33963372)

  • 1. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
    Bosch J; Lonn EM; Jung H; Zhu J; Liu L; Lopez-Jaramillo P; Pais P; Xavier D; Diaz R; Dagenais G; Dans A; Avezum A; Piegas LS; Parkhomenko A; Keltai K; Keltai M; Sliwa K; Held C; Peters RJG; Lewis BS; Jansky P; Yusoff K; Khunti K; Toff WD; Reid CM; Varigos J; Joseph P; Leiter LA; Yusuf S
    Eur Heart J; 2021 Aug; 42(31):2995-3007. PubMed ID: 33963372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.
    Lonn E; Bosch J; Pogue J; Avezum A; Chazova I; Dans A; Diaz R; Fodor GJ; Held C; Jansky P; Keltai M; Keltai K; Kunti K; Kim JH; Leiter L; Lewis B; Liu L; Lopez-Jaramillo P; Pais P; Parkhomenko A; Peters RJ; Piegas LS; Reid CM; Sliwa K; Toff WD; Varigos J; Xavier D; Yusoff K; Zhu J; Dagenais G; Yusuf S;
    Can J Cardiol; 2016 Mar; 32(3):311-8. PubMed ID: 26481083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
    Yusuf S; Bosch J; Dagenais G; Zhu J; Xavier D; Liu L; Pais P; López-Jaramillo P; Leiter LA; Dans A; Avezum A; Piegas LS; Parkhomenko A; Keltai K; Keltai M; Sliwa K; Peters RJ; Held C; Chazova I; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Sanchez-Vallejo G; McKelvie R; Pogue J; Jung H; Gao P; Diaz R; Lonn E;
    N Engl J Med; 2016 May; 374(21):2021-31. PubMed ID: 27040132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
    Yusuf S; Lonn E; Pais P; Bosch J; López-Jaramillo P; Zhu J; Xavier D; Avezum A; Leiter LA; Piegas LS; Parkhomenko A; Keltai M; Keltai K; Sliwa K; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Accini JL; McKelvie R; Pogue J; Jung H; Liu L; Diaz R; Dans A; Dagenais G;
    N Engl J Med; 2016 May; 374(21):2032-43. PubMed ID: 27039945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
    Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
    JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
    Lonn EM; Bosch J; López-Jaramillo P; Zhu J; Liu L; Pais P; Diaz R; Xavier D; Sliwa K; Dans A; Avezum A; Piegas LS; Keltai K; Keltai M; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Parkhomenko A; Khunti K; Toff WD; Reid CM; Varigos J; Leiter LA; Molina DI; McKelvie R; Pogue J; Wilkinson J; Jung H; Dagenais G; Yusuf S;
    N Engl J Med; 2016 May; 374(21):2009-20. PubMed ID: 27041480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
    Benowitz NL; Pipe A; West R; Hays JT; Tonstad S; McRae T; Lawrence D; St Aubin L; Anthenelli RM
    JAMA Intern Med; 2018 May; 178(5):622-631. PubMed ID: 29630702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
    Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
    Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
    Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial.
    Joseph P; Lonn E; Bosch J; Lopez P; Zhu J; Keltai M; Dans A; Reid C; Khunti K; Toff W; Piegas L; Kim JH; Swaminathan B; Bohm M; Yusuf S;
    Can J Cardiol; 2018 Jan; 34(1):38-44. PubMed ID: 29275880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of intensive blood pressure treatment and non-fatal cardiovascular or serious adverse events in older adults with mortality: mediation analysis in SPRINT.
    Krishnaswami A; Rich MW; Kwak MJ; Goyal P; Forman DE; Damluji AA; Solomon M; Rana JS; Kado DM; Odden MC
    Eur J Prev Cardiol; 2023 Aug; 30(10):996-1004. PubMed ID: 37185634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
    Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
    Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
    Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
    Murphy SA; Pedersen TR; Gaciong ZA; Ceska R; Ezhov MV; Connolly DL; Jukema JW; Toth K; Tikkanen MJ; Im K; Wiviott SD; Kurtz CE; Honarpour N; Giugliano RP; Keech AC; Sever PS; Sabatine MS
    JAMA Cardiol; 2019 Jul; 4(7):613-619. PubMed ID: 31116355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients.
    Bavishi C; Bangalore S; Messerli FH
    J Am Coll Cardiol; 2017 Feb; 69(5):486-493. PubMed ID: 28153104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.